Shots:
- The P-III COSMIC-311 trial evaluates Cabometyx (60mg, qd) vs PBO in a ratio (2:1) in 258 patients aged ≥12yrs. with previously treated radioactive iodine-refractory DTC across 164 sites globally
- An updated analysis showed ORR (11% vs 0%) as assessed by BIRC in ITT population including 1 CR, m-OS (19.4mos.) for Cabometyx but not estimable for PBO. The safety profile was consistent with previously observed, AEs were regulated with dose modifications, treatment discontinuation due to TEAEs (8.8% vs 0%), grade 3/4 TEAEs (62% vs 28%)
- In Sept’17, 2021, the therapy has received the US FDA’s approval for LA or metastatic DTC patients that has progressed following prior VEGFR targeted therapy
Click here to read full press release/ article | Ref: Exelixis | Image: wikipedia
The post Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021 first appeared on PharmaShots.
